Risk Intelligence
Healthcare deal delays persist
View Risks →Tata Elxsi reported Q4 FY26 revenue of ₹993.8 crore, growing 0.9% QoQ in constant currency, with EBITDA margin improving 130 bps sequentially to 24.6%.
Financial stats pending filing verification
Tata Elxsi reported Q4 FY26 revenue of ₹993.8 crore, growing 0.9% QoQ in constant currency, with EBITDA margin improving 130 bps sequentially to 24.6%. Transportation grew 2% QoQ, driven by OEM wins (now 77% of vertical revenue), while healthcare declined 13.1% due to delayed deal closures. Media & communication grew 5.6% on deal ramp-ups. Management guided for high single-digit growth in FY27 (down from earlier double-digit aspiration), citing geopolitical uncertainty and cautious client spending. Margin trajectory targets 27% exit margin by Q4 FY27 via operational efficiencies and AI adoption. Risk: healthcare recovery may slip further if deal closures continue to delay.
Healthcare deal delays persist
View Risks →Full transcript text is available on this route.
Read Transcript →Transportation vertical grew 2% QoQ in constant currency, driven by OEM wins.
Healthcare declined 13.1% QoQ due to delayed deal closures; management expects recovery in Q1.
Media & communication grew 5.6% QoQ, led by deal ramp-ups and a large multi-year win.
Utilization improved to 73%, with headroom to reach 80%+ before aggressive hiring.
Management expects high single-digit revenue growth for FY27, down from earlier double-digit aspiration, due to geopolitical uncertainty and delaye...
Healthcare declined 13.1% QoQ due to deals slipping from Q4 to Q1; if closures continue to delay, recovery may be pushed further.
View Risks →